Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.

(2017) C. Gambacorti-Passerini et al.   JOURNAL OF CLINICAL ONCOLOGY

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia

(2011) Su Jin Lee et al.   AMERICAN JOURNAL OF HEMATOLOGY

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients

(2011) M. S. Marcolino et al.   ANNALS OF ONCOLOGY

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation

(2011) A. Mazharian et al.   BLOOD

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

(2011) D. Verma et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

The skeletal effects of the tyrosine kinase inhibitor nilotinib

(2011) Susannah O'Sullivan et al.   BONE

ABL1 fusion genes in hematological malignancies: a review

(2011) Etienne De Braekeleer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

(2011) Frédéric Millot et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

(2011) K Vandyke et al.   Blood Cancer Journal

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

(2011) Jan K Hennigs et al.   BMC Pulmonary Medicine

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

(2011) Massimo Breccia et al.   Mediterranean Journal of Hematology and Infectious Diseases

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

(2010) Wei-Gang Tong et al.   CANCER

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

(2010) Ophelia Q.P. Yin et al.   CLINICAL THERAPEUTICS

Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?

(2010) Stephen Fitter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia

(2010) H Nakasone et al.   LEUKEMIA

Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

(2010) Jason N. Valent et al.   LEUKEMIA RESEARCH

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Renal Failure under Dasatinib Therapy

(2010) Sultan Ozkurt et al.   RENAL FAILURE

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

(2010) Theo D. Kim et al.   THYROID

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

(2010) Brian B. Hasinoff   TOXICOLOGY AND APPLIED PHARMACOLOGY

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

(2010) Nicole M Agostino et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

(2009) A. Quintas-Cardama et al.   BLOOD

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo

(2009) M.-P. Gratacap et al.   BLOOD

Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

(2009) M Breccia et al.   BONE MARROW TRANSPLANTATION

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

(2009) Alfonso Quintás-Cardama et al.   CANCER

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

(2009) Hagop Kantarjian et al.   CANCER

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Myeloproliferative disorder with eosinophilia and ETV6–ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors

(2009) Ranveer Nand et al.   LEUKEMIA RESEARCH

Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec™)

(2009) Jessica K. Gordon et al.   LEUKEMIA RESEARCH

c-Abl tyrosine kinase regulates cardiac growth and development

(2009) Z. Qiu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss

(2008) Helene François et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient

(2008) D Mattei et al.   BONE MARROW TRANSPLANTATION

Discoidin Domain Receptor 1 ( Ddr1 ) Deletion Decreases Atherosclerosis by Accelerating Matrix Accumulation and Reducing Inflammation in Low-Density Lipoprotein Receptor–Deficient Mice

(2008) Christopher Franco et al.   CIRCULATION RESEARCH

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

(2008) Fei Fei et al.   EXPERIMENTAL HEMATOLOGY

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA

Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia

(2008) G Caocci et al.   LEUKEMIA

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

(2008) A Quintás-Cardama et al.   LEUKEMIA

Dasatinib-induced acute hepatitis

(2008) A. Bonvin et al.   LEUKEMIA & LYMPHOMA

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

(2008) M. Breccia et al.   LEUKEMIA RESEARCH

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia

(2008) Walid Rasheed et al.   LEUKEMIA RESEARCH

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Imatinib as a Possible Cause of Severe Rhabdomyolysis

(2008) Nicolas Penel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA